Thursday, January 19, 2023 7:03:18 PM
Does anyone know if patients in the control group were told that they were in that group and asked if they want to cross over, or were they asked if they wanted to continue, and were assured they'd be continued on the vaccine.
The other question might be, were those on the vaccine asked the same question, or did they automatically just stay on the vaccine.
If it's clear that those in the control had a decision to make, it would also be clear that at that point the clinicians learned who were the control patients. The company wouldn't be told what they observed, but the clinician should have been able to clearly decern the benefits. The DSMB should have also seen the same thing.
At the time of the halt, I would have to wonder if some thought was being given to early approval, while they may have determined not to do it, they did simultaneously decide that all entering the trial would get the vaccine. I believe the regulators clearly saw the benefits and agreed to this change. I was not a shareholder at this time, it's just speculation on my part. Also, clearly back then if approval was a consideration they would have had to know that massive cleanroom construction would have been needed as FlaskWorks was an unknown at that time, I believe.
Gary
The other question might be, were those on the vaccine asked the same question, or did they automatically just stay on the vaccine.
If it's clear that those in the control had a decision to make, it would also be clear that at that point the clinicians learned who were the control patients. The company wouldn't be told what they observed, but the clinician should have been able to clearly decern the benefits. The DSMB should have also seen the same thing.
At the time of the halt, I would have to wonder if some thought was being given to early approval, while they may have determined not to do it, they did simultaneously decide that all entering the trial would get the vaccine. I believe the regulators clearly saw the benefits and agreed to this change. I was not a shareholder at this time, it's just speculation on my part. Also, clearly back then if approval was a consideration they would have had to know that massive cleanroom construction would have been needed as FlaskWorks was an unknown at that time, I believe.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
